MediPharm Labs (TSX:LABS) Total Assets: C$45.99 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MediPharm Labs Total Assets?

MediPharm Labs TSX:LABS Total Assets is C$45.99 Mil as of Jun. 2026. The stock has 4 warning signs investors should review.

MediPharm Labs's Total Assets for the quarter that ended in Jun. 2026 was C$45.99 Mil.

During the past 12 months, MediPharm Labs's average Total Assets Growth Rate was -7.20% per year. During the past 3 years, the average Total Assets Growth Rate was -5.50% per year. During the past 5 years, the average Total Assets Growth Rate was -15.90% per year.

During the past 9 years, MediPharm Labs's highest 3-Year average Total Assets Growth Rate was -5.50%. The lowest was -31.80%. And the median was -16.35%.

Total Assets is connected with ROA %. MediPharm Labs's annualized ROA % for the quarter that ended in Jun. 2026 was 0.04%. Total Assets is also linked to Revenue through Asset Turnover. MediPharm Labs's Asset Turnover for the quarter that ended in Jun. 2026 was 0.22.

MediPharm Labs  (TSX:LABS) Total Assets Explanation

Total Assets is connected with ROA %.

MediPharm Labs's annualized ROA % for the quarter that ended in Jun. 2026 is

ROA %=Net Income (Q: Jun. 2026 )/( (Total Assets (Q: Mar. 2026 )+Total Assets (Q: Jun. 2026 ))/ count )
=0.016/( (43.618+45.991)/ 2 )
=0.016/44.8045
=0.04 %

Note: The Net Income data used here is four times the quarterly (Jun. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

MediPharm Labs's Asset Turnover for the quarter that ended in Jun. 2026 is

Asset Turnover
=Revenue (Q: Jun. 2026 )/( (Total Assets (Q: Mar. 2026 )+Total Assets (Q: Jun. 2026 ))/ count )
=9.984/( (43.618+45.991)/ 2 )
=9.984/44.8045
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

MediPharm Labs Total Assets Related Terms

MediPharm Labs Total Assets Historical Data

* Premium members only.

The historical data trend for MediPharm Labs's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediPharm Labs Total Assets Chart

MediPharm Labs Annual Data
Trend Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only 92.36 65.50 63.94 53.73 45.74

MediPharm Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.31 46.60 45.74 43.62 45.99

MediPharm Labs Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

MediPharm Labs's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=35.812+9.926
=45.74

MediPharm Labs's Total Assets for the quarter that ended in Jun. 2026 is calculated as

Total Assets=Total Equity (Q: Jun. 2026 )+Total Liabilities (Q: Jun. 2026 )
=35.432+10.559
=45.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of C$45.99 Mil mean?
MediPharm Labs (TSX:LABS) has a Total Assets of C$45.99 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on MediPharm Labs and its competitors.
Is MediPharm Labs' Total Assets too high?
MediPharm Labs' current Total Assets is C$45.99 Mil.
How does MediPharm Labs' Total Assets compare to ZTS?
MediPharm Labs' Total Assets of C$45.99 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on MediPharm Labs and its competitors. MediPharm Labs's current Total Assets is C$45.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (TSX:LABS) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.07, compared to a current price of C$0.08 — trading 14.3% above its estimated fair value. The current Total Assets is C$45.99 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For MediPharm Labs (TSX:LABS), the current Total Assets is C$45.99 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediPharm Labs Business Description

Other Exchanges MEDIF:USAMLZ:Germany
Address 151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.